Could a vaccine stop lung cancer in smokers? early trial launches
NCT ID NCT03300817
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-phase trial tests a MUC1 peptide vaccine in 50 current or former smokers at high risk for lung cancer. The vaccine aims to train the immune system to recognize and attack precancerous cells before they become cancer. The study focuses on safety and whether the vaccine triggers a strong immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer could spot cancers that standard scans overlook
- Can a conversation aid empower lung cancer patients?
- Can couples coping together ease the burden of advanced cancer?
- Can a custom toolkit help indigenous smokers spot lung cancer earlier?
- Study tests if teaching doctors and patients boosts lung cancer screening
- Simple home exercises may help Smokers' lungs